Table 2.
Variables | Clinical characteristics |
Age | 27.9 (18.2-39.7) |
Male | 104 (49.3) |
Drug | 193 (91.5) |
D-penicillamine1 | 129 (61.6) |
Trientine2 | 22 (10.4) |
Zinc | 42 (19.9) |
Hepatic disease | 176 (83.4) |
Cirrhosis | 38 (21.6) |
Cirrhotic complications | 19 (10.8) |
Ascites | 10 (5.7) |
Spontaneous bacterial peritonitis | 5 (2.8) |
Esophageal varices | 10 (5.7) |
Gastric varices | 5 (2.8) |
Hepatic encephalopathy | 8 (4.5) |
Hepatocellular carcinoma | 3 (1.7) |
Neurological disease | 30 (14.2) |
Parkinsonism | 15 (50.0) |
Tremor | 3 (10.0) |
Dystonia | 4 (13.3) |
Tics | 1 (3.3) |
Dementia | 2 (6.7) |
Seizure | 7 (23.3) |
Psychiatric disease | 24 (11.4) |
Depression | 9 (37.5) |
Anxiety | 2 (8.3) |
Bipolar disorder | 4 (16.7) |
Organic affective syndrome | 3 (12.5) |
Psychosis | 4 (16.7) |
Personality disorder | 3 (12.5) |
Suicide | 4 (16.7) |
Concomitant hepatic and neurological/psychiatric diseases | 21 (10.0) |
Non-immune hemolytic anemia | 8 (3.8) |
Viral hepatitis | 7 (3.3) |
Chronic hepatitis B infection | 5 (71.4) |
Chronic hepatitis C infection | 2 (28.6) |
Metabolic factors | 17 (8.1) |
Diabetes mellitus | 3 (17.6) |
Hypertension | 7 (41.2) |
Dyslipidemia | 4 (23.5) |
Obesity | 4 (23.5) |
Alcoholism | 4 (23.5) |
Liver transplantation | 24 (11.3) |
Death | 26 (12.3) |
Twenty four patients had concomitant zinc therapy during the initial treatment phase or maintenance phase;
Eight patients had concomitant zinc therapy during the initial treatment phase or maintenance phase. Age was expressed as median (years) with interquartile range. Categorical variables were expressed as n (%).